Reflect Scientific, Inc.

What they do

Reflect Scientific manufactures and distributes ultra-low temperature freezers and blast freezers under the Cryometrix brand, which use liquid nitrogen for cryogenic storage. The company also supplies OEM products such as filtration, purification, and sealing components for gas/liquid chromatography. Its customers include hospitals, diagnostic laboratories, pharmaceutical and biotech firms, cold chain operators, universities, and government research facilities.

Revenue drivers

• Cryometrix ultra-low temperature freezers — Core product line for cryogenic storage of vaccines, DNA, RNA, proteins; marketed for energy efficiency and used in blood storage and pharmaceutical manufacturing.
• Blast freezers — Part of the Cryometrix brand, these freezers are used in applications requiring rapid freezing, contributing to the life science segment.
• Refrigerated transportation (reefers) — Application of Cryometrix technology to refrigerated trailers, eliminating hydrocarbon-fueled engines; a potential growth area as it broadens market reach.
• OEM laboratory consumables — Legacy business providing filtration, purification, sample vials, and sealing components to OEMs in the chemical analysis industry; a smaller but ongoing revenue source.

Recent performance

Revenue for the first nine months of 2024 totaled $1.53M, up from $1.11M in the same period of 2023, driven by quarterly revenues of $428,755 (Q1), $590,071 (Q2), and $514,023 (Q3). Annual revenue declined steadily from $2.8M in 2021 to $1.1M in 2023, with a net loss of $459,028 in 2023. Cash and equivalents were $1.0M as of September 30, 2024, against $2.1M in shareholder equity.

Strategy

Management aims to expand the Cryometrix product line, particularly in energy-efficient ultra-low temperature storage, capitalizing on growing demand from vaccine and biologics storage. They plan to extend the technology into refrigerated transportation (reefers) to broaden the market beyond static freezers. The company continues to supply OEM products to the life sciences industry and evaluates strategic acquisitions to add complementary technology.

Risks

• Revenue volatility and dependence on new product lines — Annual revenue declined from $2.8M in 2021 to $1.1M in 2023, and management warns that sales of new products may not reach anticipated levels.
• Operational losses — The company reported a net loss of $459,028 in 2023 and negative operating cash flows in 2022 and 2023, indicating ongoing cash burn.
• Competitive pressures — The life science and cold chain markets are competitive; pricing and product development challenges could impact demand for Cryometrix freezers.
• Dependence on single facility lease — All operations are conducted from a single leased facility in Orem, Utah, with the lease expiring November 30, 2026, exposing the company to relocation risks.

Outlook

Management sees growing need for energy-efficient, reliable ultra-low temperature storage for vaccines and biologicals, positioning Cryometrix for expansion. The application of its technology to refrigerated trailers (reefers) is expected to significantly broaden the market. Management continues to focus on research and development, regulatory approvals, and sales and marketing initiatives, with no near-term dividend plans.